View printer-friendly version
« Back
August 01, 2007 1:53 p.m.
Teva Reports Second Quarter 2007 Results

Jerusalem, Israel, August 1, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced its financial results for the second quarter ended June 30, 2007.

Second Quarter Highlights

* Record-breaking quarterly net sales of $2,386 million, up 10 percent over the second quarter of 2006,a quarter which included the launches with exclusivity of Simvastatin and Pravastatin, among the largest launches in the industry's history.

* Net income of $515 million compared to net income of $489 million and adjusted net income of $541 million in the comparable quarter of 2006.

* Diluted EPS of $0.63 compared to EPS of $0.59 and adjusted diluted EPS of $0.66 in the prior year quarter.

"This was an excellent quarter for Teva," said Shlomo Yanai, Teva's President and CEO. "We are especially pleased with our record-breaking sales figures, which show an increase of 15 percent over last quarter, and 10 percent over the second quarter of 2006--a quarter which included two of the largest launches in our company's, and the industry's, history. Our results this quarter were driven by strong performances across all our business units and geographies, by record-breaking sales of Copaxone®, and by a very successful early launch of Amlodipine/Benazepril."

Other Key Second Quarter Financial Data and Events

Net sales for the quarter reached $2,386 million, an increase of 10 percent over $2,172 million in the comparable quarter of 2006 and an increase of 15 percent over the first quarter of 2007.

Net income for the quarter was $515 million, or $0.63 per diluted share, compared to net income of $489 million or $0.59 per diluted share and to adjusted net income of $541 million, or $0.66 per diluted share, in the same period last year. Net income for the second quarter was 51 percent higher than the first quarter of 2007. The 2006 second quarter adjusted net income did not include: $31 million of inventory step-up in connection with the IVAX acquisition, $28 million of impairment and restructuring charges and $5 million of in-process R&D in associated companies, a total after tax of $52 million. The 2006 adjusted data are considered non-GAAP financial measures. Teva believes that excluding these items facilitates investors' understanding of the trends in the Company's underlying business.

Sales in all of Teva's businesses outside of the U.S. were positively impacted by favorable exchange rates, which increased sales by $69 million. However, our businesses also recorded increased expenses due to these currency movements. Overall, these exchange rates had a negligible effect on our operating profit.

Teva's second quarter North American pharmaceutical sales were $1,341 million, compared to $1,260 million in the second quarter of 2006, a quarter which included the substantial launches of Simvastatin and Pravastatin. The second quarter of 2007 benefited from an earlier than anticipated launch of Amlodipine/Benazyprill, substantially increased Oxycodone sales and higher sales of respiratory products, primarily ProAir™, Teva's non-CFC product, in the U.S., as well as increased sales of Copaxone®. This quarter, North American pharmaceutical sales represented 60 percent of total pharmaceutical sales.

The Company recorded European pharmaceutical sales of $556 million, up 13 percent over the comparable quarter last year. We benefited from strong performance in our generic business in the UK, France, Spain and Germany as well as higher sales of our respiratory business in the UK. European pharmaceutical sales represented 25 percent of total pharmaceutical sales this quarter.

Teva's international pharmaceutical sales, which accounts for 15% of total pharmaceutical sales and includes primarily Latin America (six percent of total pharmaceutical sales), Israel (four percent) and Central and Eastern European countries (four percent), increased 26 percent in the quarter to $346 million. The increase was driven by higher sales in the majority of the primary markets in these geographies.

Global in-market sales of Copaxone® amounted to $436 million, a 23 percent increase over the comparable quarter of 2006, including 24 percent growth in U.S. sales to $285 million, driven by both price increases and increased unit sales. In-market sales outside the U.S., mainly in Europe, increased by 23 percent to $151 million, and represented improved performance in several major European markets: Germany, France, Spain and the UK.

Azilect®, Teva's second innovative drug, continued its successful market acceptance trend as a beneficial option in the treatment of Parkinson's disease in the U.S. and Europe. Global in-market sales in the quarter reached $28 million compared with $6 million in the second quarter of 2006. Azilect® is now available in 27 countries.

Teva's global respiratory business recorded $181 million in sales in the second quarter of 2007, a 49 percent increase over the comparable quarter in 2006. The increase was fueled primarily by higher sales of ProAir™ HFA in the U.S. and increased sales in the UK.

API sales to third parties were $143 million in the second quarter of 2007, as compared to $145 million in the second quarter of 2006. Total API sales, including internal sales to Teva's pharmaceutical businesses, were $334 million, a decrease of six percent compared to the second quarter of 2006.

Net R&D spending for the quarter grew 14 percent as compared to the second quarter of 2006 and reached $137 million, more than half of which was expended for generic R&D.

As of July 30, 2007, Teva had 153 abbreviated new drug applications awaiting final FDA approval. Collectively, the brand products covered by these applications have annual U.S. sales of approximately $89 billion. Teva believes it is the first to file on 40 of these applications relating to products whose annual U.S. branded sales are over $37 billion. As of June 30, 2007, Teva had 134 compounds pending submissions awaiting final approval in various European countries, corresponding to 280 formulations and 2,190 dossiers.

SG&A expenses, which represented 19.7 percent of net sales, amounted to $469 million in the second quarter of 2007, as compared to $375 million, or 17.3 percent of net sales, in the second quarter of 2006 and to $456 million in the first quarter in 2007. The increase from the comparable quarter reflects higher profit sharing settlements with third parties, as well as selling and marketing expenses supporting expanding sales of Azilect® and Teva's fast-growing branded generics business.

Cash flow from operations in the second quarter amounted to $437 million, compared to $212 million in the 2006 second quarter. Free cash flow reached $256 million. Overall cash and other liquid assets at June 30, 2007 amounted to $3.1 billion.

The Board of Directors, at its meeting on July 30, 2007, declared a cash dividend for the second quarter of 2007 of NIS 0.40 (approx. 9.2 cents according to the rate of exchange on July 30, 2007) per share. The record date will be August 14, 2007, and the payment date will be August 29, 2007. Tax will be withheld at a rate of 16 percent.

Conference Call
Teva will host a conference call to discuss the Company's second quarter results today at 08:30 AM EDT. The call will be webcast and can be accessed through the Company's website at; a replay of the webcast will be available within 24 hours at the Company's web site. Alternatively, a replay of the call will be available until August 8, 2007 at midnight (EDT). For international callers please dial +1-(201)-612-7415. From the U.S., dial +1-(877)-660-6853. To access the replay, please enter both Account #: 3055 and Conference ID#:248467.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva's ability to accurately predict future market conditions including pricing and margins with regard to sales of the generic version of Protonix®, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra®, Neurontin®, Lotrel® Famvir® and Protonix®, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, the effects of competition on our innovative products, especially Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.